Thromboprophylaxis in the Sars-Cov-2 hospitalized patient
Introduction: Patients with the SARS-CoV2 virus are hospitalized for pneumonia and acute respiratory failure. Hypercoagulability, micro and macro thrombosis appear in them. The severe increase in D-dimer has led to the use of thromboprophylaxis with doses higher than the standard with controversial...
| Autores: | , |
|---|---|
| Tipo de documento: | artigo |
| Estado: | Versão publicada |
| Data de publicação: | 2021 |
| País: | Perú |
| Recursos: | Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo |
| Repositório: | Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo |
| Idioma: | espanhol |
| OAI Identifier: | oai:cmhnaaa_ojs_cmhnaaa.cmhnaaa.org.pe:article/903 |
| Acesso em linha: | https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/903 |
| Access Level: | Acceso aberto |
| Palavra-chave: | Neumonía por el Nuevo Coronavirus (2019-nCoV) infecciones por coronavirus trombosis anticoagulantes síndrome respiratorio agudo grave neumonía viral SARS-CoV-2 Pneumonia viral coronavirus infections Thrombosis Anticoagulants Respiratory Disstress Syndrome |
| Resumo: | Introduction: Patients with the SARS-CoV2 virus are hospitalized for pneumonia and acute respiratory failure. Hypercoagulability, micro and macro thrombosis appear in them. The severe increase in D-dimer has led to the use of thromboprophylaxis with doses higher than the standard with controversial results. The present article aims to guide the physician in a rational thromboprophylaxis to reduce thrombotic complications and avoid bleeding associated with anticoagulation and underlying disease. The results of randomized controlled clinical trials for optimal management of the hypercoagulable state are awaited. |
|---|